Navigation Links
PAREXEL International Announces 2-For-1 Stock Split
Date:2/11/2008

BOSTON, Feb. 11 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL) announced today that its Board of Directors has approved a 2-for-1 split of its Common Stock, which will be effected by means of a 100% stock dividend.

Holders of PAREXEL's Common Stock will receive one additional share of Common Stock for each share of Common Stock held on the record date of February 22, 2008. The additional shares will be distributed on or about March 3, 2008 by PAREXEL's transfer agent, Computershare Trust Company, N.A., and trading of PAREXEL shares on a split-adjusted basis will begin on March 4, 2008.

As of February 8, 2008, PAREXEL had approximately 28.4 million shares of Common Stock outstanding. Following the stock split, the number of outstanding shares of Common Stock will increase to approximately 56.8 million.

Josef von Rickenbach, Chairman and CEO stated, "The stock split reflects the confidence that we have for PAREXEL's future growth prospects and opportunities. We believe this action will serve to attract a broader base of investors by making our stock more accessible, while at the same time further improving liquidity."

About the Company

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 64 locations throughout 51 countries around the world, and has over 7,320 employees. For more information about PAREXEL International visit http://www.PAREXEL.com.

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward- looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended December 31, 2007 as filed with the SEC on February 7, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward- looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.

CONTACTS: James Winschel, Senior Vice President and Chief Financial

Officer

Jill Baker, Vice President of Investor Relations

+1-781-434-4118


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
2. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
3. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
4. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
5. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
6. PAREXEL Announces Date of First Quarter Fiscal Year 2008 Earnings Release and Conference Call
7. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
8. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
9. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
10. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
11. Cryo-Cell International, Inc. Reports Results for Fiscal 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today ... 31, 2015. --> --> ... loss of $29.3 million, or $0.34 loss per share, compared to ... for the same period in 2014. For the year ended December ... or $1.05 loss per share, as compared to a net loss ...
(Date:2/11/2016)... -- Wellcentive today announced it has been selected by FamilyCare ... community care organization (CCO) with more than 130,000 ... and care management solutions and services. Wellcentive,s capabilities ... managers, analysts and care managers while providing insight ... members. Oregon . ...
(Date:2/11/2016)... Buffalo, New York (PRWEB) , ... February 11, ... ... and analytical instruments for more than 150 years, continues today to pursue the ... to its line of analytical instruments: the AR9 Refractometer and the AR5 Refractometer. ...
(Date:2/10/2016)... , Feb. 10, 2016  The Maryland House of ... has announced that University of Maryland School of Medicine ... and University of Maryland Medical System President and CEO ... "Speaker,s Medallion," the highest honor given to the public ... Dean Reece and Mr. Chrencik for ...
Breaking Biology Technology:
(Date:2/9/2016)... Feb. 9, 2016 Vigilant Solutions announces today that ... (LPR) to develop a lead in a difficult homicide case. ... data to locate the suspect vehicle. Due to the ongoing ... have been omitted at the agency,s request. ... explains, "Our victim was found deceased at an intersection here ...
(Date:2/3/2016)... India , February 3, 2016 ... the new market research report "Automated Fingerprint Identification System ... Search, Latent Search), Application (Banking & Finance, Government, Healthcare, ... published by MarketsandMarkets, the market is expected to be ... CAGR of 21.0% between 2015 and 2020. The transformation ...
(Date:2/2/2016)... Feb. 2, 2016 Checkpoint Inhibitors for ... Market Are you interested in the future ... for checkpoint inhibitors. Visiongain,s report gives those predictions ... and national level. Avoid falling behind in ... opportunities and revenues those emerging cancer therapies can ...
Breaking Biology News(10 mins):